At the vanguard of Mitochondrial research
Employees: 1-10
Total raised: $20.6M
Investors 1
| Date | Name | Website |
| 04.01.2022 | ND CAPITAL | nd.capital |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 15.12.2023 | Series A | $20.6M | ND CAPITAL |
Mentions in press and media 7
| Date | Title | Description |
| 06.05.2024 | Innosuisse funded 45 Start-up innovation projects | With the Start-up innovation project, Innosuisse directly funds high potential science-based projects initiated by Swiss start-ups, giving them a financial boost to propel their market entry. The innovation projects must be based on applic... |
| 12.03.2024 | European funds to propel Swiss projects | EH Group, a startup from Nyon, designs and develops fuel cell (FC) technology to decarbonize heavy-duty mobility (trucks, trains, ferries, aviation) and large-scale stationary applications (EV superchargers, data centers, back-up). It offer... |
| 15.12.2023 | Vandria raises USD 20.6M and emerges from stealth | |
| 14.12.2023 | Vandria Announces $20.6M (CHF18M) Series A Financing Led by ND Capital to Drive CNS Clinical Program and Mitochondrial Therapeutics Platform | - |
| 14.12.2023 | Vandria Raises $20.6M in Series A Financing | Klaus Dugi, MD, CEO Vandria Vandria, a Lausanne, Switzerland-based mitochondrial therapeutics company developing small molecule mitophagy inducers, raised $20.6M in Series A funding. The round was led by ND Capital together with a small syn... |
| 06.11.2023 | A decent representation at BIO-Europe | |
| 05.06.2023 | A significant number of Swiss biotechs exhibit in Boston |